An expanded access record providing Pimavanserin tartrate in Parkinson's Disease Psychosis, sponsored by ACADIA Pharmaceuticals Inc.. Approved for marketing. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by ACADIA Pharmaceuticals Inc. · Expanded access
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
Browse Parkinson Disease studies →ACADIA Pharmaceuticals Inc. is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient meets one of the following criteria:
Exclusion Criteria:
Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ACADIA Pharmaceuticals Inc.